Sponsored

More Can Be Done for Asian American Lung Cancer Patients

December 22nd 2020

The Role of Immunotherapy in Advancing Overall Survival for Metastatic Melanoma

December 17th 2020

New Targeted Treatment Helps Delay ALK+ mNSCLC Progression

December 16th 2020

Remarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.

Rethinking How We Approach Stage 3 Lung Cancer Treatment

October 20th 2020

As ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.

SPONSORED: Multidisciplinary Cancer Care Through Virtual Collaboration

September 28th 2020

How Genomic Testing and Targeted Therapies Are Shifting the Mindset for Treating Acute Myeloid Leukemia

September 18th 2020

Questions and answers with Dr. Eunice Wang, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, an unpaid Astellas consultant

Delivering Long-Term Results for Blood Cancer Patients

July 21st 2020

While great progress has been made in developing and delivering new treatment options for chronic lymphocytic leukemia, recognizing the chronic nature of the disease and being cognizant of side effects that can have a major impact on a patient’s quality of life remains an important responsibility.

The Critical Role of Molecular Profiling in Cholangiocarcinoma

July 15th 2020

Sponsored Content

BiTE Platform and the Evolution Toward Off-The-Shelf Immuno-Oncology Approaches

June 2nd 2020

Amgen Oncology is committed to investigating innovative approaches to fighting cancer, across both hematological malignancies and solid tumors.

ASCO: New data for Alecensa shows 5-year overall survival in ALK-positive NSCLC

May 30th 2020

On Friday 29 May at the ASCO20 Virtual Scientific Programme, Roche presented updated data from the pivotal phase III ALEX clinical study.

x